$ALNY ALNYLAM PHARMACEUTICALS, INC. Insider Trading
Get free email notifications about insider trading in ALNYLAM PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ALNYLAM PHARMACEUTICALS, INC.. Insider overview, share value development, latest insider transactions and email notifications about new events in ALNYLAM PHARMACEUTICALS, INC. for free.
IRS Number: 770602661
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: ALNY
Company Address: 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE 02142
Former name: ALNYLAM PHARMACEUTICALS INC, date of change: 2002-07-24
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Market Capitalization: $3.49B
Prev close: $40.46
Average Daily Volume: 1,254,630
Days Low: $39.66
Year Low: $31.38
Year High: $80.11
ALNYLAM PHARMACEUTICALS, INC. Insiders Active In Last 3 Months
| Name | Position | Total Shares | Current Value ($) | Last 3 Months | Buy / Sell | Last Transaction | |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | President & COO | 13,374 | 541,112 | shares bought: 172,193 / shares sold: -164,234 | BUY | Apr 21 2021 | 15 days ago |
| KEATING LAURIE | EVP, Chief Legal Officer | 8,955 | 362,319 | shares bought: 191,024 / shares sold: -195,081 | SELL | Apr 21 2021 | 15 days ago |
| MARAGANORE JOHN | Chief Executive Officer | 222,272 | 8,993,125 | shares bought: 699,499 / shares sold: -626,397 | BUY | Apr 21 2021 | 15 days ago |
| Poulton Jeffrey V. | Chief Financial Officer | 4,518 | 182,798 | shares bought: 4,575 / shares sold: -1,383 | STRONG BUY | Apr 21 2021 | 15 days ago |
| Vaishnaw Akshay | President, R&D | 22,908 | 926,858 | shares bought: 281,829 / shares sold: -273,283 | BUY | Apr 21 2021 | 15 days ago |
View all ALNYLAM PHARMACEUTICALS, INC. insiders.
ALNYLAM PHARMACEUTICALS, INC. Latest Insider Transactions
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 138.48 | 107 | 14,817 | 14,119 | 14.2 K to 14.1 K (-0.75 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 137.60 | 530 | 72,928 | 14,226 | 14.8 K to 14.2 K (-3.59 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 136.84 | 1,892 | 258,901 | 14,756 | 16.6 K to 14.8 K (-11.36 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 135.41 | 203 | 27,488 | 16,648 | 16.9 K to 16.6 K (-1.20 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Payment of Exercise | F | 134.56 | 85 | 11,438 | 16,851 | 16.9 K to 16.9 K (-0.50 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Payment of Exercise | F | 131.75 | 2,266 | 298,546 | 16,936 | 19.2 K to 16.9 K (-11.80 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 140.02 | 417 | 58,388 | 19,202 | 19.6 K to 19.2 K (-2.13 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 138.64 | 622 | 86,234 | 19,619 | 20.2 K to 19.6 K (-3.07 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 137.60 | 989 | 136,086 | 20,241 | 21.2 K to 20.2 K (-4.66 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 136.76 | 1,678 | 229,483 | 21,230 | 22.9 K to 21.2 K (-7.32 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Grant | A | 0.00 | 5,083 | 0 | 22,908 | 17.8 K to 22.9 K (+28.52 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Poulton Jeffrey V. | Chief Financial Off ... | Buy | J | 0.00 | 38 | 0 | 38 | 0 to 38 |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Poulton Jeffrey V. | Chief Financial Off ... | Payment of Exercise | F | 134.49 | 50 | 6,725 | 3,135 | 3.2 K to 3.1 K (-1.57 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Poulton Jeffrey V. | Chief Financial Off ... | Payment of Exercise | F | 131.75 | 1,333 | 175,623 | 3,185 | 4.5 K to 3.2 K (-29.50 %) |
| Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Poulton Jeffrey V. | Chief Financial Off ... | Grant | A | 0.00 | 4,518 | 0 | 4,518 | 0 to 4.5 K |
View all ALNYLAM PHARMACEUTICALS, INC. insider transactions.